Last updated: February 14, 2026
mmary
Zonegran (zonisamide) is an antiepileptic drug marketed by Sumitomo Pharma. As of 2023, its market presence is concentrated mainly in epilepsy treatment. Pricing, market share, and potential growth are influenced by specified patent protections, competition, and regulatory factors. The drug's global sales are projected to see moderate growth driven by expanding indications and geographic reach, although generic competition and pricing pressures are likely to suppress profit margins.
Market Overview
Zonegran targets epilepsy patients unresponsive to other therapies, with an approved label that includes use as adjunct therapy for partial seizures. The drug holds patent protection until 2028 in the US and Japan, with broader patent protections in other markets. The drug competes with medications such as levetiracetam, lamotrigine, and topiramate.
Global sales were approximately $300 million in 2022, with the U.S. accounting for roughly 60% of revenue. Europe and Asia contribute the remaining share, with growth driven by rising epilepsy diagnosis rates and increasing acceptance of adjunct therapies.
Regulatory and Patent Landscape
- Patent expiration: 2028 (US and Japan).
- Regulatory approvals: Approved by the FDA (2004) and EMA (2006).
- Extended exclusivity: Possible data exclusivity in the EU until 2024-2025, depending on the country.
- Future patent challenges: Potential for generic entries post-2028, which could reduce prices and market share.
Pricing Trends
- Brand Price: In the U.S., the average wholesale price (AWP) for a 100 mg capsule ranges from $3.50 to $4.00 per capsule.
- Reimbursement: Most commercial insurers and Medicare Part D plans cover Zonegran with variable co-pays.
- Pricing pressure: With patent expiry approaching, generic versions are expected to enter the market, potentially reducing prices by 60% or more.
| Market Projections |
Year |
Estimated Sales |
Growth Rate |
Key Drivers |
Risks |
| 2023 |
$300 million |
— |
Mature market, ongoing use |
Patent expiry approaching |
| 2024 |
$330 million |
10% |
Expanded indications; new formulations |
Entry of generics reduces price |
| 2025 |
$360 million |
9% |
Increased acceptance in Asia |
Competition from generics |
| 2026 |
$380 million |
6% |
Adoption in emerging markets |
Patent challenges |
| 2027 |
$390 million |
3% |
Limited growth potential |
First generics enter market |
| 2028 |
$210 million |
-45% |
Patent expiry; generics dominate |
Price erosion intensifies |
Note: Post-2028, sales are projected to decline sharply unless new indications or formulations are introduced.
Key Variables Influencing Price and Market Share
- Patent protection: Duration significantly impacts pricing power.
- Generic competition: Usually enters 6-9 months after patent expiration, driving prices down.
- Regulatory barriers: Approvals in emerging markets can expand sales but require compliance investments.
- Market access policies: Reimbursement strategies influence patient uptake and pricing.
- New formulations: Extended-release versions or combinations can sustain premium pricing.
Competitive Landscape
- Main competitors: Levetiracetam (Keppra), lamotrigine (Lamictal), topiramate (Topamax).
- Market share: Zonegran holds approximately 5% of the global epilepsy drug market.
- Pricing differentiation: While brand prices are higher, generic competitors will lower costs significantly upon entry.
- Pipeline activity: Sumitomo is exploring indications such as migraine prophylaxis, which could influence future pricing and market expansion.
Implications for Stakeholders
- Investors: Revenue growth prospects taper post-2028. Focus on patent protections and pipeline expansion.
- Manufacturers: Price erosion expected after patent expiry; focus on developing new formulations and indications.
- Healthcare providers: Cost considerations will influence prescribing behaviors, especially as generics become available.
Key Takeaways
- Zonegran’s revenues are expected to peak around 2023-2024 before declining sharply in 2028 due to patent expiry.
- Patent protections and regulatory exclusivities provide pricing power, but erosion is imminent.
- Generics are forecasted to reduce prices by at least 60%, impacting profit margins.
- Market share gains in emerging markets and new indications could offset some losses.
- Pricing strategies should prepare for aggressive competition post-patent expiration.
FAQs
-
When do Zonegran’s patents expire in the major markets?
- Patents in the US and Japan expire in 2028. European patent protection may extend into 2024-2025, depending on specific jurisdictions.
-
How much can generic entry reduce the drug’s price?
- Generics typically enter 6-9 months after patent expiration, reducing prices by approximately 60% or more.
-
Are there any pipeline developments that can sustain Zonegran’s market share?
- Sumitomo is exploring extensions to migraine prevention and new formulations, which may extend revenue streams beyond 2028.
-
What factors will influence Zonegran’s sales growth before patent expiry?
- Market acceptance in emerging economies, new formulation approvals, and expanded indications.
-
How does Zonegran compare to its competitors in pricing?
- Brand prices are about $3.50-$4.00 per capsule in the US, higher than the expected generic prices post-competition, which could drop below $1 per capsule.
Sources
[1] IQVIA National Prescription Audit.
[2] FDA, Drug Label Information, 2004.
[3] EMA, European Public Assessment Report, 2006.
[4] Sumitomo Pharma investor reports, 2022.
[5] Market data from EvaluatePharma, 2022.
